Nonacog Beta Pegol

Summary

Nonacog Beta Pegol (CHEMBL2108348) is an approved protein; indicated across 1 condition including hemophilia b.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108348
Name	Nonacog Beta Pegol
Type	Protein
Max phase	4

Also known as: Nonacog beta pegol, Rebinyn, Refixia, NONACOG BETA PEGOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia B	4	MONDO:0010604	MONDO:0010604

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	6
Not specified	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01333111	PHASE3	COMPLETED	Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
NCT01386528	PHASE3	COMPLETED	Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
NCT01395810	PHASE3	COMPLETED	Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
NCT01467427	PHASE3	COMPLETED	Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
NCT02141074	PHASE3	COMPLETED	Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
NCT05365217	PHASE3	COMPLETED	A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
NCT00956345	PHASE1	COMPLETED	Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
NCT03690336	Not specified	ENROLLING_BY_INVITATION	Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
NCT03745924	Not specified	ENROLLING_BY_INVITATION	A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).